The Claim
The use of a three-range reference for plasma p-tau217 (≤0.386 pg/mL for low risk, ≥0.471 pg/mL for high risk) reduces the proportion of individuals requiring confirmatory amyloid PET scans to 10%, compared to 40–57% with clinical assessments, enabling more efficient triage in clinical practice.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Using specific plasma p-tau217 thresholds to classify Alzheimer's disease risk reduces the number of patients needing amyloid PET scans from 40–57% to 10%, compared to standard clinical assessments.
See the scientific wording
A three-range reference for plasma p-tau217 (≤0.386 pg/mL for low risk, ≥0.471 pg/mL for high risk) reduces the proportion of individuals requiring confirmatory amyloid PET scans to 10%, compared to 40–57% with clinical assessments, enabling more efficient triage in clinical practice.
When amyloid plaques build up in the brain, they cause tau proteins to become abnormally phosphorylated at position 217. These modified tau proteins leak into the bloodstream at levels that directly match the amount of brain amyloid. When plasma levels are very low or very high, they reliably indicate the absence or presence of amyloid plaques, so doctors can skip brain scans for most people.
What the research says
1 studyThis blood test can tell with high accuracy whether someone has Alzheimer's brain plaques. If the result is very low or very high, doctors can be confident without doing an expensive brain scan — meaning far fewer scans are needed.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.